76
|
Ablikim M, Achasov M, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen C, Chen G, Chen H, Chen M, Chen S, Chen T, Chen X, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui J, Dai H, Dai J, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong L, Dong M, Dong X, Du S, Egorov P, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fischer K, Fritsch M, Fu C, Gao H, Gao Y, Gao Y, Garbolino S, Garzia I, Ge P, Ge Z, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Gu Y, Guan C, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, He K, He K, Heinsius F, Heinz C, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou G, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang K, Huang L, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jia Z, Jiang H, Jiang S, Jiang X, Jiang Y, Jiao J, Jiao Z, Jin S, Jin Y, Jing M, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li L, Li M, Li P, Li S, Li S, Li T, Li W, Li W, Li X, Li X, Li X, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Limphirat A, Lin C, Lin D, Lin T, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu G, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu K, Liu L, Liu L, Liu L, Liu M, Liu P, Liu Q, Liu S, Liu T, Liu W, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu H, Lu J, Lu X, Lu Y, Lu Y, Lu Z, Luo C, Luo M, Luo T, Luo X, Lyu X, Lyu Y, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma Y, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Miao H, Min T, Mitchell R, Mo X, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Niu Y, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Pelizaeus M, Peng H, Peters K, Ping J, Ping R, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi H, Qi M, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin J, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Qu S, Rashid K, Ravindran K, Redmer C, Ren K, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan K, Shan W, Shan X, Shangguan J, Shao L, Shao M, Shen C, Shen H, Shen X, Shi B, Shi H, Shi R, Shi X, Shi X, Song J, Song W, Song Y, Sosio S, Spataro S, Stieler F, Su K, Su P, Su Y, Sun G, Sun H, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun X, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Tao L, Tao Q, Teng J, Thoren V, Tian W, Tian Y, Uman I, Wang B, Wang B, Wang C, Wang D, Wang F, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang S, Wang S, Wang T, Wang T, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wei D, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu X, Wu Y, Wu Z, Xia L, Xiang T, Xiao G, Xiao H, Xiao S, Xiao Y, Xiao Z, Xie C, Xie X, Xie Y, Xie Y, Xie Y, Xie Z, Xing T, Xu C, Xu C, Xu G, Xu H, Xu Q, Xu X, Xu Y, Xu Z, Yan F, Yan L, Yan W, Yan W, Yang H, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan S, Yuan X, Yuan Y, Yuan Z, Yue C, Zafar A, Zeng F, Zeng XZ, Zeng Y, Zhan Y, Zhang A, Zhang B, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang L, Zhang P, Zhang Q, Zhang S, Zhang S, Zhang X, Zhang X, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zhong B, Zhong C, Zhong X, Zhou H, Zhou L, Zhou X, Zhou X, Zhou X, Zhou X, Zhou Y, Zhu J, Zhu K, Zhu K, Zhu L, Zhu S, Zhu S, Zhu T, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Measurement of the branching fraction of the doubly Cabibbo-suppressed decay
D0→K+π−π0
and search for
D0→K+π−π0π0. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.105.112001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
77
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Biernat J, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao Y, Gao Y, Gao Y, Gao YG, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hansson J, Hao XQ, Harris FA, Hüsken N, He KL, Heinsius FH, Heinz CH, Held T, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HJ, Li JL, Li JQ, Li JS, Li K, Li LK, Li L, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Lin CX, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu Q, Liu SB, Liu S, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lusso S, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Mo YJ, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Poling R, Prasad V, Qi H, Qi HR, Qi KH, Qi M, Qi TY, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schönning K, Scodeggio M, Shan DC, Shan W, Shan XY, Shangguan JF, Shao M, Shen CP, Shen PX, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Su KX, Su PP, Sui FF, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun WY, Sun X, Sun YJ, Sun YK, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Tian YT, Uman I, Wang B, Wang CW, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang Y, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidenkaff P, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu GF, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yan X, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng Y, Zhang BX, Zhang G, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang S, Zhang SF, Zhang S, Zhang XD, Zhang XY, Zhang Y, Zhang YH, Zhang YT, Zhang Y, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng Y, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Probing CP symmetry and weak phases with entangled double-strange baryons. Nature 2022; 606:64-69. [PMID: 35650355 PMCID: PMC9159954 DOI: 10.1038/s41586-022-04624-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Accepted: 03/08/2022] [Indexed: 12/03/2022]
Abstract
Though immensely successful, the standard model of particle physics does not offer any explanation as to why our Universe contains so much more matter than antimatter. A key to a dynamically generated matter-antimatter asymmetry is the existence of processes that violate the combined charge conjugation and parity (CP) symmetry1. As such, precision tests of CP symmetry may be used to search for physics beyond the standard model. However, hadrons decay through an interplay of strong and weak processes, quantified in terms of relative phases between the amplitudes. Although previous experiments constructed CP observables that depend on both strong and weak phases, we present an approach where sequential two-body decays of entangled multi-strange baryon-antibaryon pairs provide a separation between these phases. Our method, exploiting spin entanglement between the double-strange Ξ- baryon and its antiparticle2 [Formula: see text], has enabled a direct determination of the weak-phase difference, (ξP - ξS) = (1.2 ± 3.4 ± 0.8) × 10-2 rad. Furthermore, three independent CP observables can be constructed from our measured parameters. The precision in the estimated parameters for a given data sample size is several orders of magnitude greater than achieved with previous methods3. Finally, we provide an independent measurement of the recently debated Λ decay parameter αΛ (refs. 4,5). The [Formula: see text] asymmetry is in agreement with and compatible in precision to the most precise previous measurement4.
Collapse
|
78
|
Nastoupil LJ, Dahiya S, Miklos DB, Reagan PM, Ulrickson M, Jung AS, Kloos I, Dong J, Chou J, Murakami J, Rodriguez K, Nahas M. KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.tps7579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS7579 Background: One mechanism by which B-cell tumors can resist the effects of CD19-targeted CAR T-cell therapy is through CD19 antigen escape (Neelapu et al. ASH 2019). Recent analyses in large B-cell lymphoma (LBCL) demonstrated that approximately one-third to two-thirds of relapses after infusion of CAR T-cell therapy were CD19 negative (Plaks et al. Blood. 2021; Spiegel, Dahiya et al. Blood. 2021; Spiegel et al. Nat Med. 2021). KITE-363 is an autologous CAR T cell transduced with a bicistronic vector with resultant expression of a CD19 CAR with a CD28 costimulatory domain and a CD20 CAR with a 41BB costimulatory domain. In preclinical studies, KITE-363 recognized and eliminated tumor cells expressing CD19 and/or CD20. KITE-363 CAR T-cell therapy has the potential to rescue CD19-negative relapsing patients with BCL as well as prevent CD19 antigen escape by minimizing selective pressure through upfront therapeutic dual targeting. This Phase 1, first-in-human, open-label, multicenter study (NCT04989803) will evaluate the safety and preliminary efficacy of KITE-363 in patients with R/R BCL. Methods: The Phase 1 design includes a 3+3 dose-escalation portion (1A), with 5 planned CAR T-cell levels, and a dose expansion portion (1B). Patients may receive optional corticosteroid bridging therapy following leukapheresis. Patients will then receive conditioning chemotherapy (cyclophosphamide and fludarabine) on Day ‒5 to Day ‒3 followed by KITE-363 infusion on Day 0. The primary endpoint for Phase 1A is the incidence of adverse events defined as dose-limiting toxicities. The primary endpoint for Phase 1B is investigator-assessed objective response rate per Lugano criteria (Cheson et al. J Clin Oncol. 2014). Secondary endpoints include complete response rate, time to next treatment, duration of response, progression-free survival, overall survival, safety, and levels of CAR T cells in blood and cytokines in serum. Eligible adult patients have histologically confirmed BCL, including LBCL, indolent non-Hodgkin lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma (HL), and BCL, unclassifiable (with features intermediate between diffuse LBCL and classical HL), that is R/R after ≥2 lines of therapy (patients with LBCL may have primary refractory disease). Other key inclusion criteria are adequate bone marrow and organ function and ECOG performance status 0‒1. Key exclusion criteria are central nervous system (CNS) involvement from lymphoma, active infection including hepatitis B and C, and clinically significant CNS disorder. This study is currently open and accruing patients. Clinical trial information: NCT04989803.
Collapse
|
79
|
Strati P, Leslie LA, Shiraz P, Budde LE, Oluwole OO, Ulrickson M, Ramakrishnan A, Sun J, Shen R, Kanska J, McCroskery P, Dong J, Schupp MA, Xu H, Patel K. Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.7567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7567 Background: Despite the success of axi-cel, ≈60% of patients (pts) have no response or relapse within ̃2 y after Tx (Jacobson C, et al. ASH 2021. #1764), highlighting the need for more therapeutic strategies. In preclinical studies, Rtx augmented CD19 CAR T-cell function and increased tumor reduction and survival in murine models via synergistic targeting with CAR T-cells (Mihara K, et al. Br J Haematol. 2010). Here, we report outcomes of ZUMA-14, a Phase 2, multicenter study of axi-cel in combination with Rtx in pts with R-LBCL after ≥2 lines of systemic therapy. Methods: Eligible pts were ≥18 y with R/R LBCL. Pts received one Rtx dose (375 mg/m2) on Day -5, a conditioning regimen of cyclophosphamide and fludarabine on Days -5, -4, and -3, and a single axi-cel infusion of 2×106 CAR T cells/kg on Day 0. Starting on Day 21 post–axi-cel infusion, pts received 1 Rtx dose every 28 d for up to 5 doses. The primary endpoint was investigator-assessed complete response (CR) rate. Secondary endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety, and biomarker assessments. The analysis reported here occurred after all treated pts had ≥12 mo of follow-up. Results: As of 12/2/21, 27 pts were enrolled, and 26 received axi-cel and ≥1 Rtx dose (15 pts received all 6 Rtx doses); 1 pt discontinued Tx due to an adverse event (AE). Median age was 63 y (range, 38-82), 54% of pts were male, 81% had stage III/IV disease, 62% had extranodal disease, 38% had elevated LDH, and 85% had an aaIPI ≥1 (35% aaIPI 2). The CR rate was 65% (95% CI, 44-83), and the ORR was 88% (95% CI, 70-98). With a median follow-up of 17 mo, 65% of the pts had ongoing response, with 57% ongoing in CR. Medians for DOR, PFS and OS were not reached. The estimated DOR and PFS rates at 12 mo were 64% and 56%, respectively. The estimated 12 mo OS rate was 76%, and 6 pts (23%) died of progressive disease. Most pts (92%) experienced Grade ≥3 AEs. Grade ≥3 cytopenias were reported in 85% of pts, with 38% ongoing on Day 30. Grade ≥3 neurologic events (NEs) occurred in 4 pts (15%), and there was no Grade ≥3 cytokine release syndrome (CRS). Median times to onset of CRS and NEs were 4 d (range, 1-7) and 6 d (range, 3-32), respectively, with median durations of 5 d (range, 2-15) and 7 d (range, 1-39). No pts experienced myelodysplastic syndrome. Median peak CAR T-cell levels were comparable to the ZUMA-1 pharmacokinetic profile. Immune-modulating cytokines, including granzyme B, IL-6, CXCL10, IFN-g and IL-2, were induced in pts following axi-cel and Rtx infusion and were more prominently elevated in responders vs non-responders. Peak Rtx levels were also elevated in responders vs non-responders. Conclusions: Results from ZUMA-14 demonstrated that axi-cel in combination with Rtx elicited a high CR rate with no new safety signals detected in pts with R-LBCL. Clinical trial information: NCT04002401.
Collapse
|
80
|
Wang H, Dong J, Bao JF, Wang CB, Lyu JX. [Analysis of the diagnostic efficiency of combining multiple laboratory hematological indicators in alpha-fetoprotein-negative hepatocellular carcinoma]. ZHONGHUA YI XUE ZA ZHI 2022; 102:1303-1310. [PMID: 35488700 DOI: 10.3760/cma.j.cn112137-20220115-00103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To establish a diagnostic model for alpha-fetoprotein-negative hepatocellular carcinoma (AFP-NHCC) by combining multiple laboratory hematological indicators and explore its clinical diagnostic efficiency. Methods: A total of 124 inpatients, including 110 males and 14 females, aged 57 (51, 66) years, who were first diagnosed with AFP-NHCC in the PLA General Hospital were included from December 2011 to June 2017. Meanwhile, 331 cases of non-HCC were enrolled as the control group, including 279 males and 52 females, aged 58 (51, 63) years old, with 47 cases of hepatitis B virus (HBV) infection, 40 cases of liver cirrhosis, 64 cases of hepatic hemangioma or cysts, 7 cases of liver nodules, 8 cases of fatty liver, 146 cases of non-liver disease and 19 health controls. Subjects in the AFP-NHCC group and the control group were divided into a training group and a validation group. A total of 196 subjects were involved in the training group, including 103 AFP-NHCC patients and 93 non-HCC patients (19 healthy controls, 25 patients with HBV infection, 22 patients with liver cirrhosis, 23 patients with hepatic hemangioma or cyst, and 4 patients with liver nodules). The differences in laboratory parameters were analyzed, and a diagnostic model of AFP-NHCC under different AFP levels was established. Likewise, 259 subjects, including 113 patients with liver disease, were involved in the validation group to verify the diagnostic efficiency of the model for AFP-NHCC. The receiver operating characteristic (ROC) curve was used to analyze the sensitivity and specificity of different models, and the area under the curve (AUC) was calculated to evaluate the diagnostic performance of different models. Results: In the training group, the indicators of AFP-NHCC diagnostic model included platelet (PLT), prothrombin activity (PTA), serum albumin (ALB), prothrombin time (PT) and carbohydrate antigen 19-9 (CA19-9), and the AUC of the model was 0.848 (95%CI: 0.786-0.911) when AFP≤5 μg/L. Similarly, the indicators of AFP-NHCC diagnostic model included PLT, PTA, ALB, PT and hematocrit (HCT), and the AUC of the model was 0.839 (95%CI: 0.780-0.897) when AFP≤10 μg/L. When AFP≤20 μg/L, the indicators of AFP-NHCC diagnostic model contained PLT, PTA, ALB, PT, HCT and AFP, and the AUC of the model was 0.866 (95%CI: 0.815-0.917). The AUC values of these three models were higher than those of AFP and CA19-9 alone for the diagnosis of AFP-NHCC [0.634 (95%CI: 0.560-0.709), 0.691 (95%CI:0.620-0.761), all P<0.05]. The indicators screened by these three models were combined to establish the final diagnostic model, and the AUC of the model was 0.873 (95%CI: 0.824-0.923), with the sensitivity of 78.6% (81/103) and the specificity of 81.7% (76/93). In the validation group, the predictive AUC of the final model in liver disease patients was 0.892 (95%CI: 0.832-0.951), with the sensitivity of 100% (21/21) and the specificity of 71.7% (66/92), while in the total validation population, the predictive AUC was 0.931 (95%CI: 0.890-0.972), with the sensitivity of 100.0% (21/21) and the specificity of 75.6% (180/238). Conclusion: The final diagnostic model includes PLT, PTA, ALB, PT, HCT, CA19-9 and AFP, which has higher sensitivity and specificity, and has good diagnostic efficiency for the clinical diagnosis of AFP-NHCC.
Collapse
|
81
|
Chu J, Lu ZL, Liu J, Fu ZT, Liu T, Dong J, Ren J, Chen XX, Guo XL, Xu A. [Spatio-temporal trend of female breast cancer mortality in Shandong Province from 1970 to 2013]. ZHONGHUA YU FANG YI XUE ZA ZHI [CHINESE JOURNAL OF PREVENTIVE MEDICINE] 2022; 56:609-613. [PMID: 35644975 DOI: 10.3760/cma.j.cn112150-20210630-00623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
The mortality of female breast cancer in Shandong Province has increased since the 1970. The differential decomposition analysis found that the slight decline in the crude mortality of breast cancer among women was entirely due to non-demographic factors during the 1970-1990, and the significant increase in the crude mortality was due to a combination of demographic and non-demographic factors since the 1990. The contribution rate of demographic factor has gradually increased from 53.5% in 2004-2005 to 59.5% in 2011-2013, while that of non-demographic factor has decreased from 46.5% to 40.5%. The women aged 45-64 years old were the major population of female breast cancer deaths, accounting for 40%-60% of total breast cancer deaths in different times, and then the mortality in female aged 55-64 years old increased rapidly, with increases of 52.12%, 115.19% and 29.01% in 2011-2013 over the 1970-1974, 1990-1992 and 2004-2005, respectively (Z=-7.342,P<0.001). Compared with 1970-1974, the age-standardized mortality rate of rural women increased by 41.86% in 2011-2013 (Z=-17.933, P<0.001), and that of urban women increased by 18.62% in 2011-2013 (Z=-25.642, P<0.001). The age-standardized mortality rate of breast cancer in urban women was higher than that in rural women in different times (all P<0.05). The spatial scan analysis found that eastern Shandong Province was found to be a sustained high-risk area for death, and other high-risk areas were transferred from north to southwest of Shandong between 1970 and 2013.
Collapse
|
82
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai J, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Dong X, Du S, Egorov P, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fritsch M, Fu C, Gao Y, Gao Y, Gao Y, Garzia I, Ge P, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Guan C, Guo A, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, He K, He K, Heinsius F, Heinz C, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou G, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Hüsken N, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jiang H, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Jing M, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li P, Li S, Li W, Li W, Li X, Li X, Li X, Li Z, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Limphirat A, Lin C, Lin D, Lin T, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu G, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu K, Liu L, Liu M, Liu P, Liu Q, Liu Q, Liu S, Liu T, Liu T, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi H, Qi M, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin J, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan W, Shan X, Shangguan J, Shao M, Shen C, Shen H, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song J, Song W, Song Y, Sosio S, Spataro S, Stieler F, Su K, Su P, Sui F, Sun G, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun X, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Teng J, Thoren V, Tian W, Tian Y, Uman I, Wang B, Wang C, Wang D, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang S, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xu C, Xu G, Xu Q, Xu W, Xu X, Xu Y, Yan F, Yan L, Yan W, Yan W, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan Y, Yuan Z, Yue C, Zafar A, Zeng XZ, Zeng Y, Zhang A, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang L, Zhang S, Zhang S, Zhang S, Zhang X, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu T, Zhu W, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Partial wave analysis of
J/ψ→γη′η′. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.105.072002] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
83
|
Gao HL, Dong J, Xu J, Yu XJ. [Efficacy of conversion therapy and direct surgical resection in patients with metastatic pancreatic neuroendocrine tumors]. ZHONGHUA YI XUE ZA ZHI 2022; 102:1007-1013. [PMID: 35399020 DOI: 10.3760/cma.j.cn112137-20210805-01749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To explore the prognosis of Chinese patients with metastatic pancreatic neuroendocrine tumor (PanNET) treated with conversion therapy and surgical resection. Methods: The pathological data and prognostic information was retrospectively collected of patients with metastatic PanNET treated in Fudan University Shanghai cancer center from January 2010 to May 2021, and propensity score matching was used to analyze the prognosis difference between conversion treatment followed surgery and direct surgery. Results: There were 58 males and 43 females in 101 patients with metastatic PanNET. The age raged from 18 to 74 years, with a median age of 51 years. A total of 88 patients received primary tumor with liver metastases resection, 1 receied of primary tumor resection and 12 received primary tumor resection and combined organs or extrahepatic metastases. Multivariate analysis showed that R2(HR=1.943,95%CI:1.262-2.990,P=0.003)resection and G3(HR=1.876,95%CI:1.001-3.516,P=0.05) were independent risk factors for postoperative progression of metastatic patients. There were 63 patients (62.4%) who had received direct surgery, and 38 patients (37.6%) who had received preoperative conversion therapy. The conversion therapy had a higher proportion of T3/T4 stage (68.1% vs 39.7%, P=0.007), resection with combined organs/extrahepatic metastasis (26.3% vs 9.5%, P=0.005) and R2 resection (71.1% vs 42.9%, P=0.005). The median progression-free survival (mPFS) between conversion therapy and direct surgery had no statistically significant, but after the propensity score matching the mPFS of the conversion therapy group was significantly longer than direct surgery group (HR=0.442,95%CI:0.207-0.943,P=0.027). Conclusions: Conversion therapy for partially metastatic PanNET is better than that of direct surgery. Radical resection and grade are independent prognostic factors for metastatic PanNET after resection.
Collapse
|
84
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai JP, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao Y, Gao Y, Gao YG, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Guan CY, Guo AQ, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Andersson WI, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JL, Li JQ, Li JS, Li K, Li LK, Li L, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu Q, Liu SB, Liu T, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan W, Shan XY, Shangguan JF, Shao M, Shen CP, Shen HF, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Sui FF, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Tian WH, Tian YT, Uman I, Wang B, Wang CW, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu CJ, Xu GF, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng X, Zeng Y, Zhang AQ, Zhang BX, Zhang G, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang S, Zhang SF, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Observation of the Singly Cabibbo Suppressed Decay Λ_{c}^{+}→nπ^{+}. PHYSICAL REVIEW LETTERS 2022; 128:142001. [PMID: 35476477 DOI: 10.1103/physrevlett.128.142001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/05/2022] [Accepted: 03/01/2022] [Indexed: 06/14/2023]
Abstract
The singly Cabibbo-suppressed decay Λ_{c}^{+}→nπ^{+} is observed for the first time with a statistical significance of 7.3σ by using 3.9 fb^{-1} of e^{+}e^{-} collision data collected at center-of-mass energies between 4.612 and 4.699 GeV with the BESIII detector at BEPCII. The branching fraction of Λ_{c}^{+}→nπ^{+} is measured to be (6.6±1.2_{stat}±0.4_{syst})×10^{-4}. By taking the upper limit of branching fractions of Λ_{c}^{+}→pπ^{0} from the Belle experiment, the ratio of branching fractions between Λ_{c}^{+}→nπ^{+} and Λ_{c}^{+}→pπ^{0} is calculated to be larger than 7.2 at the 90% confidence level, which disagrees with most predictions of the available phenomenological models. In addition, the branching fractions of the Cabibbo-favored decays Λ_{c}^{+}→Λπ^{+} and Λ_{c}^{+}→Σ^{0}π^{+} are measured to be (1.31±0.08_{stat}±0.05_{syst})×10^{-2} and (1.22±0.08_{stat}±0.07_{syst})×10^{-2}, respectively, which are consistent with previous results.
Collapse
|
85
|
Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med 2022; 28:735-742. [PMID: 35314842 PMCID: PMC9018426 DOI: 10.1038/s41591-022-01731-4] [Citation(s) in RCA: 114] [Impact Index Per Article: 57.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 01/26/2022] [Accepted: 02/01/2022] [Indexed: 12/19/2022]
Abstract
High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov NCT03761056) we evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of first-line treatment in 40 patients with high-risk LBCL. This trial has completed accrual. The primary outcome was complete response rate (CRR). Secondary outcomes were objective response rate (ORR), duration of response (DOR), event-free survival (EFS), progression-free survival (PFS), overall survival (OS), assessment of safety, central nervous system (CNS) relapse and blood levels of CAR T cells and cytokines. The primary endpoint in efficacy-evaluable patients (n = 37) was met, with 78% CRR (95% confidence interval (CI), 62-90) and 89% ORR (95% CI, 75-97). As of 17 May 2021 (median follow-up, 15.9 months), 73% of patients remained in objective response; median DOR, EFS and PFS were not reached. Grade ≥3 cytokine release syndrome (CRS) and neurologic events occurred in three patients (8%) and nine patients (23%), respectively. There were no treatment-related grade 5 events. Robust CAR T-cell expansion occurred in all patients with a median time to peak of 8 days. We conclude that axi-cel is highly effective as part of first-line therapy for high-risk LBCL, with a manageable safety profile.
Collapse
|
86
|
Fang K, Ma AJ, Dong J, Jiang B, Xie J, Wei YQ, Xie C, Qi K, Zhao Y, Dong Z. [Investigation on knowledge, attitude and behavior of salt reduction in adults of Beijing in 2017]. ZHONGHUA YU FANG YI XUE ZA ZHI [CHINESE JOURNAL OF PREVENTIVE MEDICINE] 2022; 56:340-345. [PMID: 35381656 DOI: 10.3760/cma.j.cn112150-20210422-00398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To explore the knowledge, attitude and behavior of salt reduction in adults of Beijing in 2017. Methods: Based on the monitoring data of chronic diseases and corresponding risk factors in adults of Beijing in 2017, the indicators of salt reduction knowledge, attitude and behavior of 13 240 participants aged 18-79 years old were analyzed. The awareness rate, attitude support rate and behavior rate were calculated by complex weighting method, and compared among different age groups, genders, residential areas, and history of hypertension. The proportion of people taking various salt reduction measures to the total number of people was compared. Results: The awareness rate of recommended daily salt intake, the awareness of hypertension caused or aggravated by more salt intake, the attitude support rate and behavior rate of adults were 31.77%, 88.56%, 90.27% and 53.86%, respectively. After weighted adjustment, the awareness rate of recommended daily salt intake was 31.08%, which increased with age (χ2trend=431.56, P<0.001) and education level (χ2trend=95.44, P<0.001). The awareness rate of women was higher than that of men (χ²=118.89, P<0.001), and the awareness rate of population in urban areas was higher than that of population in suburban areas (χ²=34.09, P=0.001). The awareness rate of hypertension caused or aggravated by eating more salt was 86.73%. The support rate of salt reduction attitude was 90.45%. The rate of salt-reducing behavior was 54.05%. Among different salt reduction measures, reducing salt when cooking was the most common measure (52.41%), while the least common one (35.22%) was using low sodium salt. Logistic regression model analysis showed that the gender, age, education level, self-reported history of hypertension, awareness of salt recommendation, awareness of hypertension caused or aggravated by eating more salt, and salt reduction attitude were significantly associated with salt reduction behavior. Conclusion: In 2017, adults in Beijing have a basic understanding of the impact of high-salt diet on health and support salt reduction, but the rate of salt reduction behavior is still relatively low. There are obvious gender and age differences, and the salt reduction measure is simple. Targeted measures should be taken to promote the formation of salt reduction behavior.
Collapse
|
87
|
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Sherman M, Dong J, Giovanetti A, Yang Y, Lui C, Bashir Z, Jung AS, Jacobson CA. Long-Term Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Transplant Cell Ther 2022. [DOI: 10.1016/s2666-6367(22)00236-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
88
|
Chou J, Arihara Y, Budka J, Huang L, Tiwari G, Falk A, Jacobson CA, Rodig S, Armand P, Miklos DB, Neelapu SS, Locke FL, Lekakis LJ, Ghobadi A, Lin Y, Dong J, Milletti F, Mattie M, Bot A, Ritz J. Pre and Post-Treatment CD27+ T Cells Track with Clinical Efficacy of Axi-Cel in DLBCL Patients. Transplant Cell Ther 2022. [DOI: 10.1016/s2666-6367(22)00368-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
89
|
Jacobson CA, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, Muñoz J, Siddiqi T, Shen RR, Bot A, Dong J, Singh K, Spooner C, Karalliyadda R, Kim JJ, Zheng Y, Neelapu SS. Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL). Transplant Cell Ther 2022. [DOI: 10.1016/s2666-6367(22)00171-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
90
|
Neelapu SS, Dickinson M, Muñoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Primary Analysis (PA) of Zuma-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients (Pts) with High-Risk Large B-Cell Lymphoma (LBCL). Transplant Cell Ther 2022. [DOI: 10.1016/s2666-6367(22)00173-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
91
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao Y, Gao Y, Gao YG, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Andersson WI, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JL, Li JQ, Li JS, Li K, Li LK, Li L, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Lin CX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu L, Liu MH, Liu PL, Liu Q, Liu Q, Liu SB, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Pogodin S, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan W, Shan XY, Shangguan JF, Shao M, Shen CP, Shen HF, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Su KX, Su PP, Sui FF, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Tian WH, Tian YT, Uman I, Wang B, Wang CW, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu GF, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng XZ, Zeng Y, Zhang AQ, Zhang BX, Zhang G, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang S, Zhang SF, Zhang S, Zhang XD, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Measurement of the Cross Section for e^{+}e^{-}→Hadrons at Energies from 2.2324 to 3.6710 GeV. PHYSICAL REVIEW LETTERS 2022; 128:062004. [PMID: 35213186 DOI: 10.1103/physrevlett.128.062004] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 01/21/2022] [Indexed: 06/14/2023]
Abstract
Based on electron-positron collision data collected with the BESIII detector operating at the Beijing Electron-Positron Collider II storage rings, the value of R≡σ(e^{+}e^{-}→hadrons)/σ(e^{+}e^{-}→μ^{+}μ^{-}) is measured at 14 center-of-mass energies from 2.2324 to 3.6710 GeV. The resulting uncertainties are less than 3.0% and are dominated by systematic uncertainties.
Collapse
|
92
|
Wei YQ, Ma AJ, Fang K, Dong J, Xie J, Xie C, Qi K, Dong Z. [Analysis of the current status and related factors of oral nutritional supplements intake among 18-79 years old in Beijing in 2017]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2022; 43:227-233. [PMID: 35184489 DOI: 10.3760/cma.j.cn112338-20210819-00661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To understand the current status of taking nutrient supplements for residents aged 18 to 79 years old in Beijing and its related factors. Methods: Data were gathered from the 2017 Beijing Non-communicable and Chronic Disease Surveillance Program. Multiple classified cluster sampling method was used, and participants aged 18-79 were sampled from 16 districts. The questionnaire included chronic diseases and related risk factors, health knowledge, and oral nutritional supplements within 12 months. Multivariate logistic regression models were established to analyze associated factors that affect the intake of nutrient supplements. Results: The weighted prevalence of supplements use was 13.1% among 12 696 subjects within the past 12 months. The proportions of multivitamins (4.7%), B vitamins (4.5%), and folic acid (3.2%) were higher. The prevalence of supplement use of young people (18-39 years old) and the elderly (60-79 years old) was higher than middle-aged people (40-59 years old) (χ2=54.09, P<0.001). Except for the age group of 70-79 years old, the consumption rate of women was significantly higher than that of men (P<0.05). After adjusting age and sex, among patients with hypertension, diabetes, or dyslipidemia, the control rates of blood pressure, glucose and lipids of patients who take nutrient supplements were higher than those who do not (P<0.05). And participants who took nutrient supplements had a more heightened awareness rate of health knowledge, such as the hazards of smoking and second-hand smoke, and recommended amount of salt per day (P<0.001). The multi-factor logistic analysis found that nutrient supplement-related factors include women, old age, higher education level, living in urban, insufficient physical activity, sleeping problems, active physical examination, blood pressure control among patients, and health knowledge (P<0.05). Conclusions: The factors of nutrient supplements use were related to sex, age, education level, health status, and health literacy. We should pay attention to key populations and guide them to establish the correct concept of taking nutrient supplements.
Collapse
|
93
|
LI X, Xu X, Pi H, Dong J. POS-699 The relationship between staphylococcus aureus nasal carriage and peritoneal dialysis-related Infection. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
94
|
ABI N, Xu X, Dong J. POS-225 ASSOCIATION OF SERUM ADIPOKINES AND RESTING ENERGY EXPENDITURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
95
|
Ding JW, Dong J, Dong L, Qu XX, Xian JF, Li DM. [Analysis of the cognitive effects of monocular blindness and related influencing factors]. [ZHONGHUA YAN KE ZA ZHI] CHINESE JOURNAL OF OPHTHALMOLOGY 2022; 58:41-45. [PMID: 34979792 DOI: 10.3760/cma.j.cn112142-20210108-00009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To investigate the cognitive effects of monocular blindness and related influencing factors. Methods: A cross-sectional study was conducted. The patients with monocular blindness (the age of onset <16 years) were enrolled from Beijing Tongren Eye Center, Beijing Tongren Hospital between January 2018 and June 2020. The Montreal cognitive assessment (MoCA) scale was applied to assess seven cognitive domains including visuospatial and executive function, naming, attention, etc. Based on MoCA scores, all the patients were classified into two groups: normal cognitive functions and cognitive impairment. Spearman's correlation was used to perform the single factor analysis of the influencing factors of cognitive functions. Multivariate linear regression analyses were applied to identify the independent influencing risk factors. Results: A total of 45 patients with monocular blindness were enrolled. There were 25 males and 20 females, with age at testing being (27±10) years.The incidence of cognitive impairment in 45 patients was 60.0% (27/45). The abnormal items ranking from a high to low rate were language (95.6%, 43 cases), delayed recall (75.6%, 34 cases), visuospatial and executive function (60.0%, 27 cases), abstract (44.4%, 20 cases), attention (35.6%, 16 cases), naming (20.0%, 9 cases), and orientation (0%). There were statistically significant differences (all P<0.05) in total score (21.9±3.3 vs. 27.4±1.4), visuospatial and executive function (3.2±1.7 vs. 4.6±0.7), naming (2.7±0.6 vs. 2.9±0.2), attention (5.3±1.0 vs. 5.8±0.4), language (1.1±0.8 vs. 1.8±0.8), abstract (1.1±0.8 vs. 1.8±0.5) and delayed recall (2.3±1.3 vs. 4.4±0.8) between two groups of patients with and without cognitive impairment. Spearman's correlation analysis showed visuospatial and executive functions, attention, abstract and MoCA total score were positively correlated with education years (correlation coefficients being 0.355, 0.424, 0.434 and 0.370, respectively; all P<0.05). Multiple linear regression showed that duration of blindness was correlated with naming (β=-0.325), and years of education correlated with attention (β=0.472), abstract ability (β=0.441) and MoCA total score (β=0.390) (all P<0.05). Conclusions: Monocular blindness may affect language, delayed memory and visuospatial executive functions. The duration of blindness is an independent risk factor, and higher education is a protective factor of the cognitive impairment.
Collapse
|
96
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao Y, Gao Y, Gao Y, Gao YG, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KL, Heinsius FH, Heinz CH, Held T, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li JL, Li JQ, Li JS, Li K, Li LK, Li L, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Lin CX, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu L, Liu MH, Liu PL, Liu Q, Liu Q, Liu SB, Liu S, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Mo YJ, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Pogodin S, Poling R, Prasad V, Qi H, Qi HR, Qi KH, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan DC, Shan W, Shan XY, Shangguan JF, Shao M, Shen CP, Shen HF, Shen PX, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Su KX, Su PP, Sui FF, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun WY, Sun X, Sun YJ, Sun YK, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Tian WH, Tian YT, Uman I, Wang B, Wang CW, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang Y, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu GF, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yan X, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Yuncu A, Zafar AA, Zeng Y, Zhang AQ, Zhang BX, Zhang G, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang S, Zhang SF, Zhang S, Zhang XD, Zhang XY, Zhang Y, Zhang YH, Zhang YT, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng Y, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. First Measurement of Polarizations in the Decay D^{0}→ωφ. PHYSICAL REVIEW LETTERS 2022; 128:011803. [PMID: 35061485 DOI: 10.1103/physrevlett.128.011803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Accepted: 12/14/2021] [Indexed: 06/14/2023]
Abstract
Using a data sample corresponding to an integrated luminosity of 2.93 fb^{-1} collected at a center-of-mass energy sqrt[s]=3.773 GeV by the BESIII detector, the decay D^{0}→ωϕ is observed for the first time. The branching fraction is measured to be (6.48±0.96±0.40)×10^{-4} with a significance of 6.3σ, where the first and second uncertainties are statistical and systematic, respectively. An angular analysis reveals that the ϕ and ω mesons from the D^{0}→ωϕ decay are transversely polarized. The 95% confidence level upper limit on longitudinal polarization fraction is set to be less than 0.24, which is inconsistent with current theoretical expectations and challenges our understanding of the underlying dynamics in charm meson decays.
Collapse
|
97
|
Zhao G, Guo D, Li L, Yang C, Dong J. The Association between Dietary Magnesium Intake and Telomere Length in Adults with Hypertension. J Nutr Health Aging 2022; 26:1010-1015. [PMID: 36437769 DOI: 10.1007/s12603-022-1856-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND Dietary micronutrients are significantly associated with telomere length, as shown in multiple studies. However, no study has investigated the association between magnesium intake and telomere length in adults with hypertension. METHODS Participants were included from the National Health and Nutrition Examination Survey (NHANES) in 1999-2000 and 2001-2002. Dietary magnesium intake was assessed using the 24 - hour recall method and the telomere length of leukocytes was measured using polymerase chain reaction (PCR). A multivariate regression model was then used to assess the association between dietary magnesium intake and telomere length in adults with hypertension. RESULTS Our final analysis included 2199 hypertensive adults (46.79% males) with a mean dietary magnesium intake of 254.82±133.47 mg/day. Linear regression, adjusted for race, sex, age, smoking, uric acid, and other variables, showed that every 1 mg increase in dietary magnesium intake was associated with a 0.20 (95% CI: 0.01, 0.39, p = 0.043) longer telomere length in all participants. In the ≥45 years age group, there was a statistically significant association between the telomere length and dietary magnesium (95% CI: 0.16, 0.63, p <0.001). CONCLUSIONS This study suggests that increased magnesium intake is associated with a longer telomere length in hypertensive adults, especially in those ≥45 years of age. However, further research is needed to determine a causal relationship.
Collapse
|
98
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Dong X, Du S, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fritsch M, Fu C, Gao Y, Gao Y, Gao Y, Gao Y, Garzia I, Ge P, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Gu S, Gu Y, Guan C, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, Hüsken N, He K, Heinsius F, Heinz C, Held T, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Ikegami Andersson W, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jiang H, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li P, Li S, Li W, Li W, Li X, Li X, Li X, Li Z, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Lin C, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu K, Liu L, Liu M, Liu P, Liu Q, Liu Q, Liu S, Liu S, Liu T, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lusso S, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Mo Y, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Poling R, Prasad V, Qi H, Qi H, Qi K, Qi M, Qi T, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan D, Shan W, Shan X, Shangguan J, Shao M, Shen C, Shen P, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song W, Song Y, Sosio S, Spataro S, Su K, Su P, Sui F, Sun G, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun W, Sun X, Sun Y, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Teng J, Thoren V, Tian W, Uman I, Wang B, Wang C, Wang D, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidenkaff P, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xu G, Xu Q, Xu W, Xu X, Xu Y, Yan F, Yan L, Yan W, Yan W, Yan X, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan X, Yuan Y, Yuan Z, Yue C, Yuncu A, Zafar A, Zeng Y, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang S, Zhang S, Zhang S, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu T, Zhu W, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Cross sections for the reactions
e+e−→K+K−π+π−(π0)
,
K+K−K+K−(π0)
,
π+π−π+π−(π0)
,
pp¯π+π−(π0)
in the energy region between 3.773 and 4.600 GeV. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.112009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
99
|
Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, Song J, Huang L, Xu Z, Fu JL, Li Y, Xu R, Li TT, Dong J, Cai J, Li G, Xie Y, Shi M, Li Y, Zhang Y, Xie WF, Wang FS. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine 2021; 75:103789. [PMID: 34963099 PMCID: PMC8709782 DOI: 10.1016/j.ebiom.2021.103789] [Citation(s) in RCA: 44] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 12/15/2021] [Accepted: 12/16/2021] [Indexed: 02/07/2023] Open
Abstract
Background The long-term consequences of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study assessed the 1-year outcomes in patients with severe COVID-19, who were recruited in our previous UC-MSC clinical trial. Methods In this prospective, longitudinal, cohort study, 100 patients enrolled in our phase 2 trial were prospectively followed up at 3-month intervals for 1 year to evaluate the long-term safety and effectiveness of UC-MSC treatment. The primary endpoint was an altered proportion of whole-lung lesion volumes measured by high-resolution CT. Other imaging outcomes, 6 min walking distance (6-MWD), lung function, plasma biomarkers, and adverse events were also recorded and analyzed. This trial was registered with ClinicalTrials.gov (NCT04288102). Findings MSC administration improved in whole-lung lesion volume compared with the placebo with a difference of −10.8% (95% CI: −20.7%, −1.5%, p = 0.030) on day 10. MSC also reduced the proportion of solid component lesion volume compared with the placebo at each follow-up point. More interestingly, 17.9% (10/56) of patients in the MSC group had normal CT images at month 12, but none in the placebo group (p = 0.013). The incidence of symptoms was lower in the MSC group than in the placebo group at each follow-up time. Neutralizing antibodies were all positive, with a similar median inhibition rate (61.6% vs. 67.6%) in both groups at month 12. No difference in adverse events at the 1-year follow-up and tumor markers at month 12 were observed between the two groups. Interpretation UC-MSC administration achieves a long-term benefit in the recovery of lung lesions and symptoms in COVID-19 patients. Funding The National Key R&D Program of China, the Innovation Groups of the National Natural Science Foundation of China, and the National Science and Technology Major Project.
Collapse
|
100
|
Dong J, Pacella M, Liu Y, Zhao L. Surface engineering and the application of laser-based processes to stents - A review of the latest development. Bioact Mater 2021; 10:159-184. [PMID: 34901537 PMCID: PMC8636930 DOI: 10.1016/j.bioactmat.2021.08.023] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 08/04/2021] [Accepted: 08/20/2021] [Indexed: 12/21/2022] Open
Abstract
Late in-stent thrombus and restenosis still represent two major challenges in stents’ design. Surface treatment of stent is attracting attention due to the increasing importance of stenting intervention for coronary artery diseases. Several surface engineering techniques have been utilised to improve the biological response in vivo on a wide range of biomedical devices. As a tailorable, precise, and ultra-fast process, laser surface engineering offers the potential to treat stent materials and fabricate various 3D textures, including grooves, pillars, nanowires, porous and freeform structures, while also modifying surface chemistry through nitridation, oxidation and coatings. Laser-based processes can reduce the biodegradable materials' degradation rate, offering many advantages to improve stents’ performance, such as increased endothelialisation rate, prohibition of SMC proliferation, reduced platelet adhesion and controlled corrosion and degradation. Nowadays, adequate research has been conducted on laser surface texturing and surface chemistry modification. Laser texturing on commercial stents has been also investigated and a promotion of performance of laser-textured stents has been proved. In this critical review, the influence of surface texture and surface chemistry on stents performance is firstly reviewed to understand the surface characteristics of stents required to facilitate cellular response. This is followed by the explicit illustration of laser surface engineering of stents and/or related materials. Laser induced periodic surface structure (LIPSS) on stent materials is then explored, and finally the application of laser surface modification techniques on latest generation of stent devices is highlighted to provide future trends and research direction on laser surface engineering of stents. Compared conventional surface engineering with laser-based methods for biomedical devices. Explained the influence of texture geometry and surface chemistry on stents biological response. Reviewed state of the art in laser surface engineering of stents for improved biological response. Reviewed state of the art in laser surface engineering to control degradation of bioresorbable stents. Highlighted novel laser surface engineering designs for improved stents'performance.
Collapse
|